The federal government has widened its probe of prescription drug maker Johnson & Johnson for its marketing practices. Specifically, the company is coming under further scrutiny for its antipsychotic Risperdal; Topamax, a treatment for epilepsy and migraines; and Natrecor, for patients suffering from severe heart failure.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.